Comprehensive Stock Comparison
Compare BridgeBio Oncology Therapeutics Inc. (BBOT) vs Incyte Corporation (INCY) Stock
Analyze side-by-side fundamentals, valuation, growth, and profitability to decide which stock is the better buy.
Selected Stocks
Add up to 10 tickers. Use presets or search to get started.
Quick Verdict
| Category | Winner | Why |
|---|---|---|
| Value | INCY | Lower P/E (13.4x vs 21.8x) |
| Stability / Safety | BBOT | Beta 0.26 vs INCY's 0.61 |
| Dividends | Tie | Neither pays a meaningful dividend |
| Momentum (1Y) | INCY | +37.8% vs BBOT's -9.2% |
| Efficiency (ROA) | INCY | 18.5% ROA vs BBOT's -23.7%, ROIC 51.1% vs -64.9% |
Who Each Stock Is For
Income & stability
Growth exposure
Long-term compounding (10Y)
Sleep-well-at-night portfolio
Defensive / Recession hedge
Business Model
What each company does and how it makes money
BridgeBio Oncology Therapeutics is a clinical-stage biopharmaceutical company developing precision cancer drugs targeting specific genetic mutations in tumors. It generates revenue primarily through research collaborations and licensing deals — with future income dependent on successful drug development and commercialization — though currently in pre-revenue stage as it advances its clinical pipeline. The company's competitive advantage lies in its specialized focus on difficult-to-target oncogenes like KRAS and PI3Kα, leveraging BridgeBio Pharma's broader platform for drug discovery and development.
Incyte is a biopharmaceutical company that discovers, develops, and commercializes proprietary therapeutics for oncology and inflammatory diseases. It generates revenue primarily from sales of its flagship drug JAKAFI (ruxolitinib) for myelofibrosis and polycythemia vera — which accounts for the vast majority of its revenue — along with newer oncology products like PEMAZYRE and ICLUSIG. The company's moat lies in its deep expertise in kinase inhibition — particularly JAK inhibitors — and its established commercial infrastructure for hematology-oncology products.
Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
Segment breakdown not available.
Financial Metrics Comparison
Side-by-side fundamentals across 2 stocks. BestLagging
Financial Scorecard
INCY leads in 3 of 6 categories — strongest in Financial Metrics and Profitability & Efficiency. 2 categories are tied.
Financial Metrics (TTM)
INCY and BBOT operate at a comparable scale, with $5.1B and $0 in trailing revenue.
| Metric | BBOTBridgeBio Oncolog… | INCYIncyte Corporation |
|---|---|---|
| RevenueTrailing 12 months | $0 | $5.1B |
| EBITDAEarnings before interest/tax | -$124M | $1.4B |
| Net IncomeAfter-tax profit | -$115M | $1.3B |
| Free Cash FlowCash after capex | -$96M | $1.4B |
| Gross MarginGross profit ÷ Revenue | — | +91.8% |
| Operating MarginEBIT ÷ Revenue | — | +26.4% |
| Net MarginNet income ÷ Revenue | — | +25.0% |
| FCF MarginFCF ÷ Revenue | — | +26.3% |
| Rev. Growth (YoY)Latest quarter vs prior year | — | +27.8% |
| EPS Growth (YoY)Latest quarter vs prior year | -20.0% | +43.1% |
Valuation Metrics
At 15.8x trailing earnings, INCY trades at a 28% valuation discount to BBOT's 21.8x P/E.
| Metric | BBOTBridgeBio Oncolog… | INCYIncyte Corporation |
|---|---|---|
| Market CapShares × price | $794M | $20.1B |
| Enterprise ValueMkt cap + debt − cash | $793M | $17.1B |
| Trailing P/EPrice ÷ TTM EPS | 21.80x | 15.80x |
| Forward P/EPrice ÷ next-FY EPS est. | — | 13.40x |
| PEG RatioP/E ÷ EPS growth rate | — | — |
| EV / EBITDAEnterprise value multiple | — | 11.89x |
| Price / SalesMarket cap ÷ Revenue | — | 3.91x |
| Price / BookPrice ÷ Book value/share | 0.88x | 3.93x |
| Price / FCFMarket cap ÷ FCF | — | 14.84x |
Profitability & Efficiency
INCY delivers a 24.9% return on equity — every $100 of shareholder capital generates $25 in annual profit, vs $-26 for BBOT. On the Piotroski fundamental quality scale (0–9), INCY scores 7/9 vs BBOT's 4/9, reflecting strong financial health.
| Metric | BBOTBridgeBio Oncolog… | INCYIncyte Corporation |
|---|---|---|
| ROE (TTM)Return on equity | -25.7% | +24.9% |
| ROA (TTM)Return on assets | -23.7% | +18.5% |
| ROICReturn on invested capital | -64.9% | +51.1% |
| ROCEReturn on capital employed | -83.3% | +29.0% |
| Piotroski ScoreFundamental quality 0–9 | 4 | 7 |
| Debt / EquityFinancial leverage | — | 0.01x |
| Net DebtTotal debt minus cash | -$2M | -$3.0B |
| Cash & Equiv.Liquid assets | $2M | $3.1B |
| Total DebtShort + long-term debt | $0 | $69M |
| Interest CoverageEBIT ÷ Interest expense | — | 686.52x |
Total Returns (with DRIP)
A $10,000 investment in INCY five years ago would be worth $12,718 today (with dividends reinvested), compared to $9,843 for BBOT. Over the past 12 months, INCY leads with a +37.8% total return vs BBOT's -9.2%. The 3-year compound annual growth rate (CAGR) favors INCY at 9.6% vs BBOT's -0.5% — a key indicator of consistent wealth creation.
| Metric | BBOTBridgeBio Oncolog… | INCYIncyte Corporation |
|---|---|---|
| YTD ReturnYear-to-date | -18.4% | -0.1% |
| 1-Year ReturnPast 12 months | -9.2% | +37.8% |
| 3-Year ReturnCumulative with dividends | -1.6% | +31.6% |
| 5-Year ReturnCumulative with dividends | -1.6% | +27.2% |
| 10-Year ReturnCumulative with dividends | -1.6% | +37.8% |
| CAGR (3Y)Annualised 3-year return | -0.5% | +9.6% |
Risk & Volatility
BBOT is the less volatile stock with a 0.26 beta — it tends to amplify market swings less than INCY's 0.61 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. INCY currently trades 90.2% from its 52-week high vs BBOT's 67.5% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | BBOTBridgeBio Oncolog… | INCYIncyte Corporation |
|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 0.26x | 0.61x |
| 52-Week HighHighest price in past year | $14.87 | $112.29 |
| 52-Week LowLowest price in past year | $8.50 | $53.56 |
| % of 52W HighCurrent price vs 52-week peak | +67.5% | +90.2% |
| RSI (14)Momentum oscillator 0–100 | 40.7 | 44.9 |
| Avg Volume (50D)Average daily shares traded | 267K | 1.6M |
Analyst Outlook
Wall Street rates BBOT as "Buy" and INCY as "Buy". Consensus price targets imply 132.6% upside for BBOT (target: $23) vs 7.5% for INCY (target: $109).
| Metric | BBOTBridgeBio Oncolog… | INCYIncyte Corporation |
|---|---|---|
| Analyst RatingConsensus buy/hold/sell | Buy | Buy |
| Price TargetConsensus 12-month target | $23.33 | $108.90 |
| # AnalystsCovering analysts | 2 | 44 |
| Dividend YieldAnnual dividend ÷ price | — | — |
| Dividend StreakConsecutive years of raises | — | — |
| Dividend / ShareAnnual DPS | — | — |
| Buyback YieldShare repurchases ÷ mkt cap | 0.0% | +0.1% |
Historical Charts
Charts are rendered on first load. Hover for details.
Chart 1Total Return — 5 Years (Rebased to 100)
| Stock | Feb 24 | Feb 26 | Change |
|---|---|---|---|
| BridgeBio Oncology … (BBOT) | 100 | 118.06 | +18.1% |
| Incyte Corporation (INCY) | 100 | 173.87 | +73.9% |
Incyte Corporation (INCY) returned +27% over 5 years vs BridgeBio Oncology … (BBOT)'s -2%. A $10,000 investment in INCY 5 years ago would be worth $12,718 today (including dividends reinvested).
Chart 2Revenue Growth — 10 Years
| Stock | 2016 | 2025 | Change |
|---|---|---|---|
| BridgeBio Oncology … (BBOT) | $0.00 | $0.00 | — |
| Incyte Corporation (INCY) | $1.1B | $5.1B | +365.0% |
Incyte Corporation's revenue grew from $1.1B (2016) to $5.1B (2025) — a 18.6% CAGR.
Chart 3P/E Ratio History — 7 Years
| Stock | 2018 | 2025 | Change |
|---|---|---|---|
| Incyte Corporation (INCY) | 124.7 | 15.4 | -87.7% |
Incyte Corporation has traded in a 15x–461x P/E range over 7 years; current trailing P/E is ~16x.
Chart 4EPS Growth — 10 Years
| Stock | 2016 | 2025 | Change |
|---|---|---|---|
| BridgeBio Oncology … (BBOT) | -0 | 0.46 | +22004.8% |
| Incyte Corporation (INCY) | 0.54 | 6.41 | +1087.0% |
Incyte Corporation's EPS grew from $0.54 (2016) to $6.41 (2025) — a 32% CAGR.
Chart 5Free Cash Flow — 5 Years
BridgeBio Oncology Therapeutics Inc. generated $-1M FCF in 2024. Incyte Corporation generated $1B FCF in 2025 (+138% vs 2021).
BBOT vs INCY: Frequently Asked Questions
9 questions · data-driven answers · updated daily
01Is BBOT or INCY a better buy right now?
Incyte Corporation (INCY) offers the better valuation at 15.8x trailing P/E (13.4x forward), making it the more compelling value choice. Analysts rate BridgeBio Oncology Therapeutics Inc. (BBOT) a "Buy" — based on 2 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which has the better valuation — BBOT or INCY?
On trailing P/E, Incyte Corporation (INCY) is the cheapest at 15.8x versus BridgeBio Oncology Therapeutics Inc. at 21.8x.
03Which is the better long-term investment — BBOT or INCY?
Over the past 5 years, Incyte Corporation (INCY) delivered a total return of +27.2%, compared to -1.6% for BridgeBio Oncology Therapeutics Inc. (BBOT). A $10,000 investment in INCY five years ago would be worth approximately $13K today (assuming dividends reinvested). Over 10 years, the gap is even starker: INCY returned +37.8% versus BBOT's -1.6%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
04Which is safer — BBOT or INCY?
By beta (market sensitivity over 5 years), BridgeBio Oncology Therapeutics Inc. (BBOT) is the lower-risk stock at 0.26β versus Incyte Corporation's 0.61β — meaning INCY is approximately 139% more volatile than BBOT relative to the S&P 500.
05Which has better profit margins — BBOT or INCY?
Incyte Corporation (INCY) is the more profitable company, earning 25.0% net margin versus 0.0% for BridgeBio Oncology Therapeutics Inc. — meaning it keeps 25.0% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: INCY leads at 26.1% versus 0.0% for BBOT. At the gross margin level — before operating expenses — INCY leads at 91.5%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
06Is BBOT or INCY more undervalued right now?
Analyst consensus price targets imply the most upside for BBOT: 132.6% to $23.33.
07Which pays a better dividend — BBOT or INCY?
None of the stocks in this comparison currently pay a material dividend. All are effectively zero-yield and should be held for capital appreciation rather than income.
08Is BBOT or INCY better for a retirement portfolio?
For long-horizon retirement investors, BridgeBio Oncology Therapeutics Inc. (BBOT) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0.26)). Both have compounded well over 10 years (BBOT: -1.6%, INCY: +37.8%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
09What are the main differences between BBOT and INCY?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both. In terms of investment character: BBOT is a small-cap quality compounder stock; INCY is a mid-cap deep-value stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that beat both.